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Neurobiology of Disease
Mitofusin 2 Is Necessary for Transport of Axonal
Mitochondria and Interacts with the Miro/Milton Complex
Albert Misko,1 Sirui Jiang,1 IgaWegorzewska,1 Jeffrey Milbrandt,1,2 and Robert H. Baloh1,2
1Department of Neurology and 2Hope Center for Neurological Diseases, Washington University School of Medicine, St. Louis, Missouri 63110
Mitofusins (Mfn1 andMfn2) are outer mitochondrial membrane proteins involved in regulatingmitochondrial dynamics. Mutations in
Mfn2 cause Charcot-Marie-Tooth disease (CMT) type 2A, an inherited disease characterized by degeneration of long peripheral axons,
but the nature of this tissue selectivity remains unknown. Here, we present evidence that Mfn2 is directly involved in and required for
axonal mitochondrial transport, distinct from its role in mitochondrial fusion. Live imaging of neurons cultured fromMfn2 knock-out
mice or neurons expressing Mfn2 disease mutants shows that axonal mitochondria spend more time paused and undergo slower
anterograde and retrograde movements, indicating an alteration in attachment to microtubule-based transport systems. Furthermore,
Mfn2 disruption altered mitochondrial movement selectively, leaving transport of other organelles intact. Importantly, both Mfn1 and
Mfn2 interact withmammalianMiro (Miro1/Miro2) andMilton (OIP106/GRIF1) proteins, members of themolecular complex that links
mitochondria to kinesinmotors. Knockdown ofMiro2 in cultured neurons produced transport deficits identical to loss ofMfn2, indicat-
ing that both proteins must be present at the outer membrane to mediate axonal mitochondrial transport. In contrast, disruption of
mitochondrial fusion via knockdown of the inner mitochondrial membrane protein Opa1 had no effect on mitochondrial motility,
indicating that loss of fusion does not inherently alter mitochondrial transport. These experiments identify a role for mitofusins in
directly regulatingmitochondrial transport andoffer important insight into the cell type specificity andmolecularmechanismsof axonal
degeneration in CMT2A and dominant optic atrophy.
Introduction
As principal mediators of ATP production and calcium buffer-
ing, mitochondria actively distribute to areas of high energy de-
mand and calcium flux (Berthold et al., 1993; Li et al., 2004;
Misgeld et al., 2007). Based on this principle, disruption of axonal
transport has long been proposed as a potential mechanism in
human neurodegenerative diseases (Duncan and Goldstein,
2006; De Vos et al., 2008).
Mitochondrial transport is regulated by a series of molecular
adaptors that mediate the attachment of mitochondria to molec-
ularmotors (Hollenbeck and Saxton, 2005; Kang et al., 2008; Li et
al., 2009). In Drosophila, connection of mitochondria to kinesin
motors involves the outer mitochondrial membrane (OMM)
protein dMiro, which indirectly attaches to kinesin heavy chain
via the adaptor protein Milton (Guo et al., 2005; Glater et al.,
2006). In mammals, two isoforms of Miro (Miro1 and Miro2)
and Milton (OIP106 and GRIF1) have been identified and are
proposed to act in a similar manner (Fransson et al., 2006).
In addition to constant movement, mitochondria also un-
dergo frequent fission and fusion events (Chan, 2006). The mi-
tochondrial fusion apparatus consists primarily of mitofusin 1
and mitofusin 2 (Mfn1 and Mfn2) located on the OMM, and
Opa1 located on the inner mitochondrial membrane (Rojo et al.,
2002; Chen et al., 2003; Eura et al., 2003; Wong et al., 2003;
Cipolat et al., 2004). Both the mitofusins and Opa1 are dynamin
family GTPases and are believed to tether opposing membranes
and facilitate their fusion. Although the precise reason for mito-
chondrial fusion remains unclear, interruption of mitochondrial
fusion (via loss of Opa1 orMfn1/2) leads to loss ofmitochondrial
potential and diminished oxidative phosphorylation, indicating
it is critical for maintaining mitochondrial function (Olichon et
al., 2003; Chen et al., 2005).
Dominantly inherited point mutations inMFN2 are the most
commonly identified cause of axonal Charcot-Marie-Tooth
(CMT) disease (designated CMT2A); however, it is still not clear
how mutations in this ubiquitously expressed protein lead to
relatively selective degeneration of long peripheral axons (Zuchner
et al., 2004; Lawson et al., 2005; Verhoeven et al., 2006). Muta-
tions inOPA1 disrupt mitochondrial fusion and lead to degener-
ation of optic nerve axons, referred to as dominant optic atrophy
(Votruba et al., 2003; Newman, 2005). In some cases, CMT2A
mutant forms of MFN2 are unable to mediate mitochondrial
fusion in fibroblasts, whereas others are completely competent to
promote fusion (Detmer and Chan, 2007). Interestingly, exoge-
nous expression of disease mutant forms of MFN2 in cultured
sensory neurons leads to a profound abnormality mitochondrial
transport (Baloh et al., 2007), and mice overexpressing disease
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mutant MFN2 in motor neurons show markedly abnormal axonal
mitochondrialdistribution(Detmeret al., 2008).Thesedata support
thatMFN2influencesmitochondrial transport;however, themolec-
ular basis of this effect hasnot beendefined, and it has beenobserved
only in the context of MFN2 overexpression.
Here, we show that loss of Mfn2 profoundly and selectively
disrupts axonal mitochondrial transport and that Mfn2 directly
interacts with OMMproteins and adaptors involved inmitochon-
drial transport. Furthermore, we show that disrupting mitochon-
drial fusion via Opa1 knockdown does not itself disrupt axonal
mitochondrial transport. These data indicate that Mfn2 plays an
integral role in the regulation of mitochondrial transport and has
important implications for understanding the pathophysiology of
CMT2A and dominant optic atrophy.
Materials andMethods
Plasmids and silencing RNAs. Human wild-type MFN2 (wtMFN2) and
MFN2 disease mutant constructs were previously described (Baloh et al.,
2007). For small interfering RNA (siRNA) constructs, targeting sequences
were generated using the Dharmacon siDesign Center and cloned into the
FSP-si construct as described previously (Araki et al., 2004). Silencing was
confirmed via quantitative PCR. Myc-tagged Miro1 and Miro2 constructs
were a gift from Dr. Pontus Aspenstro¨m (Karolinska Institute, Stockholm,
Sweden) and were subcloned into a lentiviral expression vector. For Mfn1,
GRIF1, and OIP106 constructs, cDNAs were obtained from Open Biosys-
tems, and N-terminal tags (His-Mfn1, Flag-GRIF1, and Flag-OIP106) were
inserted via PCRmutagenesis and sequenced fully.
Production of Mfn2 knock-out mice. A targeting construct that inserted
the full-length human MFN2 cDNA with the H361Y mutation and a
hemagglutinin (HA) tag, aswell as a phosphoglycerine kinase (PGK)-neo
selection cassette, into the first coding exon of mouse Mfn2 was electro-
porated into mouse embryonic stem cells. Clones were screened for ho-
mologous recombination via Southern blotting, a properly targeted
clone was injected into blastocysts to generate
chimeras, and germline transmission was con-
firmed. Because of either the PGK promoter or
the removal of other endogenous mouse se-
quences, we found that the chimeric mRNA
transcript was barely detectable, and no HA-
tagged protein was expressed from the targeted
allele. Living homozygous Mfn2H361Y/H361Y
mice were not observed from Mfn2H361Y/ 
Mfn2H361Y/ breedings. However, timed preg-
nancies of Mfn2H361Y/  Mfn2H361Y/ mice
showed embryonic day 12.5 (E12.5) embryos at
25%, indicating that they die between this time
and birth, slightly later than a previously charac-
terizedMfn2-null line (Chenet al., 2003). Immu-
noblotting of nervous tissue from Mfn2H361Y/
H361Y embryos showed that noMfn2 proteinwas
beinggenerated, indicating that thesemice repre-
sent a complete knock-out of Mfn2 protein, and
hencewe refer to themasMfn2/ in this article.
Dorsal root ganglion cultures. Dorsal root
ganglion (DRG) cultures were performed from
embryonic rats or mice on gestational day 15.5
or 12.5, respectively. Dorsal root ganglia were
dissected out, dissociated using trypsin/EDTA,
and plated directly onto 24-well plates coated
with laminin and poly-D-lysine. Cultures were
maintained in Neurobasal medium with B27
supplement (Invitrogen), 50 ng/ml NGF, 5mM
glutamine, and antibiotics. Addition of
5-fluorouracil for the first 4 d in culture was
used as an antimitotic treatment.
Lentivirus production and infection. Lentivi-
ruses were produced as described previously
(Baloh et al., 2007). Briefly, human embryonic
kidney (HEK) 293T cells were plated onto six-well plates and transfected
using Mirus reagent with a packaging vector (8.91), envelope vector
(vesicular stomatitis virus-glycoprotein), and transfer vector encoding
the gene to be expressed.Media was changed once at 12 h and collected at
24 and 48 h, pooled, and applied directly to DRG cultures resulting in
95% infection efficiency.
Transfection of DRG cultures. To label mitochondria in a small subset
of neurons within a culture, Liptofectamine 2000 (Invitrogen) was used
according to the manufacturer’s specifications to introduce a mitochondri-
ally targeted DsRed. Briefly, 0.4 g of plasmid DNA was diluted in 25 l of
Opti-MEM (Invitrogen) and combined with 0.5 l of transfection reagent
diluted in 25 l. The mixture was incubated for 20 min and added to cells.
Mediumwas changed 6 h later to remove the transfection reagent.
Measurement of mitochondrial transport. For imaging of rat DRG neu-
rons expressing Mfn2 wild-type or disease constructs or silencing RNA
constructs, cultures were infected at 4 d in vitro (DIV4) and subsequently
transfected with mitochondrial marker on DIV7. Imaging of mitochon-
drial movements was possible on DIV10–13. For mouse DRG neurons
from Mfn2/ mice, infections were performed on DIV4 and infected
again withmitochondrial marker onDIV7. Imaging was then performed
onDIV10–13. All imaging was performed in a climate-controlled cham-
ber (In Vivo Scientific) at 37°C and 5% CO2 and images were acquired
with a Cool Snap HQ2 CCD camera (Photometrics) mounted on a Ni-
kon Eclipse Ti-U microscope. Images were acquired at 40 magnifica-
tion every 1 s for 5 min. Kymographs were then generated and analyzed
using MetaMorph software (Molecular Devices). Mitochondria were
classified as either moving or stationary based on whether they achieved
a displacement of2 m. Constant velocity movement segments iden-
tified on kymographs were measured for mitochondria that were classi-
fied as moving. A velocity cutoff of 0.1 m/s was established, and all
movements below this velocity were treated as time spent paused. Mea-
surements were pooled, and the time that mitochondria spent moving at
given velocities was binned and represented on a histogram as a percent-
age of the total time that mitochondria spent moving above the 0.1m/s
Figure 1. CMT2A-associatedMFN2mutants alter the transport of axonal mitochondria. Mitochondria in cultured DRG neurons
expressing wtMFN2 or R94Q were labeled with mito-RFP and imaged by time-lapse microscopy. A, Kymograph analysis of mito-
chondrial movements in R94Q-expressing cells reveal diminished numbers of movingmitochondria. B, Mitochondria from R94Q-
expressing neurons spent more time paused between anterograde and retrograde movements than did mitochondria from
controls. (*p 0.005, t test; n number of axons fromwhich image stacks were created). Each condition contained a total of at
least 500 observed mitochondria. C, Velocity distributions representing the amount of time that mitochondria from wtMFN2- or
R94Q-expressing neurons spentmoving at indicated velocities. Anterograde velocities are above the x-axis, and retrograde veloc-
ities are below the x-axis. There was a shift in both the anterograde and retrograde velocity distributions of mitochondria from
R94Q-expressing neurons toward slower velocities. The differences were statistically significant as determined by rank-sum test
analysis ( p 0.001).D, Size–frequency distributions of axonalmitochondria fromwtMFN2-, R94Q-, and H361Y-expressing cells
show that CMT2A disease mutants decrease mitochondrial lengths.
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cutoff. Pauses in movement segments were measured between consecu-
tive anterograde or retrograde movements and represented as a percent-
age of the total time that moving mitochondria were observed. In some
cases, images of single axons accompanying kymographs were processed
using the “emboss” filter in Adobe Photoshop for clarity.
Coimmunoprecipitation. HEK 293T cells were transfected using Mirus
with constructs containing His-Mfn1, EGFP-Mfn2, myc-Miro1, myc-
Miro2, Flag-GRIF1, Flag-OIP106, or Bluescript plasmid as a vector con-
trol. Cells were lysed in 1%TritonX-100, 5mMEDTA, 300mMNaCl, and
50 mM Tris-HCl, pH 7.5 (Glater et al., 2006), with complete protease
inhibitor mixture (Roche). Cells were lysed at 4°C for 30 min and clari-
fied by spinning at 10,000  g, and protein concentration was deter-
mined using the BCA protein assay (Thermo Scientific). Equal amounts
of protein from each lysate were raised to a final volume of 500 l,
precleared with protein A Sepharose beads (Invitrogen), incubated with
1 l of anti-myc (Cell Signaling Technology) or anti-Flag (Sigma) anti-
body for 1 h at room temperature, and then incubated overnight at 4°C
with protein A Sepharose beads. Beads were washed three timeswith lysis
buffer and boiled in Laemmli buffer before separation by SDS-PAGE.
Western blot analysis was performed with the same antibodies, anti-
Mfn2 (Sigma) or anti-Mfn1 (Novus Biologicals), at a 1:1000 dilution in
5% nonfat milk/TBS-Tween 20.
Results
CMT2A-associatedMFN2mutants disrupt both anterograde
and retrograde mitochondrial transport
Previous studies indicate thatCMT2A-associatedMFN2mutants
produce a marked decrease in overall mitochondrial mobility in
axons of cultured sensory neurons (Baloh et al., 2007), and alter
mitochondrial distribution in motor axons of transgenic mice
(Detmer et al., 2008). To clearly define the abnormality in mito-
chondrial transport in CMT2A mutant-expressing DRG neu-
rons, we introduced wtMFN2 or mutant MFN2 constructs using
lentivirus (99% infection) that were expressed at equal levels
(supplemental Fig. S1, available at www.jneurosci.org as supple-
mental material), followed by transfection with a mitochondri-
ally targeted RFP that labels only a small number of neurons,
allowing precise analysis of anterograde and retrograde move-
ments in single axons. In wtMFN2-expressing cells, kymograph
analysis of mitochondrial movements consistently depicted
fast persistent movements in both anterograde and retrograde
directions, accompanied by slower moving and stationary mito-
chondria. In contrast, CMT2A disease mutant MFN2 (R94Q)-
expressing neurons showed a striking absence of the fast
persistent movements, with the amount of time spent paused
between anterograde and retrograde movements significantly
greater in mutant-expressing neurons than in wtMFN2-expressing
controls (Fig. 1A,B). Additionally, mitochondria from mutant-
expressing neurons moved at slower velocities in the anterograde
and retrograde directions (Fig. 1C). These findings indicate thatmi-
tochondria in MFN2mutant-expressing cells were unable to either
initiateor sustain fast processivemovements, suggestingadisruptionof
microtubule-basedmitochondrial transport.We also observed that ex-
pressionof theR94Qmutant produced smaller fragmented axonalmi-
tochondria, consistent with the previously reported inability of this
mutant tomediate fusion in fibroblasts (Detmer andChan, 2007). To-
gether, these findings indicate thatmutantMFN2expression influences
both transport and fusionof axonalmitochondria.
CMT2A-associatedMFN2mutants do not alter transport of
other organelles
To determine whether this was a direct effect on mitochondrial
mobility or a global disruption of all organellar transport, we
performed sequential time-lapse imaging of mitochondria and
either endosomes or peroxisomes in single axons of DRG neu-
rons expressing wtMFN2 or MFN2 disease mutants (R94Q and
H361Y) (Fig. 2). Axons expressing wild-type or mutant MFN2
were coinfectedwith amito-RFPmitochondrialmarker (Fig. 2A)
and a RhoB-green fluorescent protein (GFP) endosomal marker
(Fig. 2B), and time-lapse imaging with kymograph analysis was
performed on endosomes andmitochondria. Despite themarked
abnormality in mitochondrial transport observed in mutant
MFN2-expressing axons (Fig. 2A,C), endosomes imaged in the
same axons showed normal movement (Fig. 2B,D). Similarly,
imaging of peroxisomes (visualized with a GFP-SKL fusion pro-
tein) showed normal movement in both wild-type and mutant
MFN2-expressing axons (Fig. 2E–G). These observations indi-
cate that MFN2 disease mutants specifically alter mitochondrial
transport and do not globally disrupt organellar transport via
alterations in microtubules or intra-axonal signaling pathways.
Mfn2 is required for the proper transport of
axonal mitochondria
The specific disruptionofmitochondrial transport byMFN2disease
mutants suggests that MFN2 may directly regulate microtubule-
based mitochondrial transport. To determine whether MFN2 is
Figure 2. CMT2A-associated MFN2 mutants specifically disrupt mitochondrial transport.
A, B, DRG neurons expressing the H361Y or R94Q MFN2 disease mutants were coinfected with
mito-RFP (A) and RhoB-GFP (B) mitochondrial and endosomal markers, respectively. Mutant-
expressing neurons revealed diminished mitochondrial mobility (A, kymograph) in the same
axons that showed normal endosomal transport (B, kymograph). C, D, The percentage of mo-
bile mitochondria is significantly decreased in R94Q- and H361Y- compared with wtMFN2-
expressingneurons (*p0.001),whereas the percentage ofmobile endosomes in these axons
was normal. E, F, Overlay images of phase contrast and EGFP-SKL (which labels peroxisomes) in
wtMFN2 (E)- andH361Y (F )-expressing DRG axons.G, Similar to endosomes, the percentage of
mobile peroxisomes was unaltered by the expression of MFN2 mutants.
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necessary formitochondrial transport, we culturedDRGneurons
from Mfn2-null (Mfn2/) embryos (supplemental Fig. S2,
available at www.jneurosci.org as supplemental material). Lenti-
virus infection of DRGneurons withmito-RFP showed amarked
delay in the migration of mitochondria out into axons of
Mfn2/ neurons compared with DRG neurons from wild-type
littermates (Fig. 3A,B). As expected, mitochondria from
Mfn2/ axons were smaller than controls, consistent with a
mitochondrial fusiondefect (Fig. 3D). Live imaging andkymograph
analysis revealed abnormal mitochondrial
movement patterns in Mfn2/ neurons
that mirrored the movement abnormalities
seen in MFN2 disease mutant-expressing
neurons (Fig. 3A,B, kymographs). This ef-
fect was again specific to mitochondrial
transport, as peroxisomal transport was
normal in these neurons (supplemental
Fig. S3, available at www.jneurosci.org as
supplemental material). Reintroduction
of wild-type MFN2 by lentiviral infection
into Mfn2/ cultures fully rescued both
the delay in migration and the abnormal
mitochondrial movement patterns (Fig.
3C, kymograph). Similar to the MFN2
disease mutant-expressing neurons, mi-
tochondria in Mfn2/ neurons spent a
greater amount of time paused between
anterograde and retrograde movements
(Fig. 3E,F ) and more time at slower
velocities in both anterograde and
retrograde directions than in controls
(Fig. 3G).
Interestingly, overexpression of Mfn1
also restored mitochondrial pause time
and velocity distributions to normal lev-
els (Fig. 3E,F ). Mfn2 and Mfn1 are
highly homologous and are known to
have overlapping functions in mediating
mitochondrial fusion (Chen et al., 2003).
Analysis of Mfn1 and Mfn2 expression in
embryonic fibroblasts and DRG neurons
showed that both Mfn1 and Mfn2 are ex-
pressed in DRG neurons, although Mfn2
is higher in neurons than in fibroblasts
(supplemental Fig. S1, available at www.
jneurosci.org as supplemental material).
Therefore, although both are able to
mediate mitochondrial transport, the
severe transport abnormalities in Mfn2/
DRG neurons suggest that Mfn1 levels
in these cells are not sufficient to com-
pensate for the loss of Mfn2.
These findings indicate that Mfn2 is
necessary for propermitochondrial trans-
port and that CMT2A-associated Mfn2
mutants disrupt this function in a
dominant-negative manner. The in-
creased pause time of mitochondria ob-
served in Mfn2/ axons suggests that
Mfn2 may either directly promote mito-
chondrial attachment to microtubules or
maintain the processivity of the microtu-
bule motors kinesin and dynein.
Mfn2 andMfn1 interact with components of the
mitochondrial transport apparatus
The findings that loss of Mfn2 or expression of CMT2A disease
mutants leads to a selective disruption of fast processive mito-
chondrial movements suggest that mitofusins could play a
direct role in the regulation of microtubule-based mitochon-
drial transport. We therefore investigated whether MFN2
could interact with molecules that link mitochondria to
Figure 3. Mfn2 is required for normal axonal transport of mitochondria. To assess the effects of loss of Mfn2 on mitochondrial
mobility, we analyzed mitochondrial transport in DRG neurons cultured from Mfn2 knock-out animals. A–C, DRG cultures from
wild-type (A) or Mfn2/ (B) mice infected with mito-RFP and imaged 4 d after infection at 10magnification coupled with
corresponding kymographs from single axons. Corresponding axons are presented above each kymograph as an embossed image
for clarity.B, Diminishednumbers ofmitochondria areobserved inMfn2/axonsdue toadelay in theoverall outwardmigration
of mitochondria that is corrected by reintroduction of wild-type human MFN2 (C, Mfn2 rescue). D, Size–frequency histogram of
mitochondria shows a decrease in the lengths ofmitochondria observed inMfn2/ axons that is restoredwith reintroduction of
MFN2 (Mfn2 rescue). E–G, Kymograph analysis of mitochondrial movements in individual MFN2/ axons showed a profound
abnormality in transport, resembling the deficit observed with expression of MFN2 disease mutants. The moving mitochondria
fromMfn2/ axons spent more time paused betweenmovements (E, F ) (*p 0.001, t test; n is number of axons fromwhich
kymographs were generated), moved at slower velocities in the anterograde and retrograde directions (G), and were completely
rescued by expression of either Mfn2 or Mfn1.
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microtubule-based transport motors.
Miro1 and Miro2 are OMM Rho-like
GTPases that linkmitochondria to kine-
sin, and Drosophila Miro is essential for
mitochondrial transport in flies (Frans-
son et al., 2006; Glater et al., 2006; Ma-
caskill et al., 2009b; Russo et al., 2009).
Coimmunoprecipitation experiments
demonstrated that Mfn2 and Mfn1 are
capable of interacting with either Miro1
or Miro2 when exogenously expressed
in HEK 293T cells, with an apparently
stronger interaction observed between
Mfn2:Miro2 than Mfn2:Miro1 (Fig.
4A,B). We next examined OIP106 and
GRIF, homologues of the Drosophila
Milton protein that interacts with both
Miro proteins and kinesin (Fransson et
al., 2006). We found that Mfn2 and
Mfn1 also coimmuniprecipitated with
OIP106 andGRIF1 (Fig. 4C–F). Finally, we
investigated whether the mitofusins di-
rectly interact with kinesin. Because
Kif5C, a conventional kinesin-1 super-
family member, is highly expressed in
neurons, we used exogenously expressed
Kif5C for our coimmunoprecipitation ex-
periments but found that neither Mfn2
nor Mfn1 directly interacted with Kif5C
(Fig. 4G,H ). Similarly, no interaction
between Mfn2 and kinesin light chain
was observed (data not shown). To in-
vestigate whether Mfn2 could play a role
in “anchoring” mitochondria, we also
examined whether Mfn2 could interact
with syntaphilin (Synph). Synph is an
OMM protein that prevents mitochondria
frommoving by anchoring them tomicrotu-
bules(Kangetal.,2008).However,neitherwt-
MFN2 nor R94Q coimmunoprecipitated
with Synph (Fig. 4I).
These experiments demonstrate that
Mfn2 and Mfn1 interact with compo-
nents of the kinesin-based mitochondrial
molecular transport apparatus, providing
an explanation for how loss of Mfn2 dis-
rupts mitochondrial transport. Of note,
the CMT2A-associated MFN2 mutants
(R94Q andH361Y)maintained the ability
to interact with Miro1/2 and OIP106/
GRIF1 (supplemental Fig. S4, available
at www.jneurosci.org as supplemental
material). Furthermore, mutant MFN2
proteins did not disrupt either the inter-
action between OIP106 and kinesin or
the interaction between Miro2 and
OIP106 (supplemental Fig. S4, available at www.jneurosci.org as
supplemental material). Therefore, the disruption of mito-
chondrial transport observed with disease mutant MFN2 ex-
pression is likely through altered regulation of the kinesin
transport apparatus (processivity, attachment to microtu-
bules) rather than simple disruption of Mfn:Miro:OIP106
complex formation.
Knockdown of Miro2 produces a mitochondrial transport
abnormality similar to loss of Mfn2
DrosophilaMiro is required for both anterograde and retrograde
transport of axonal mitochondria (Guo et al., 2005; Russo et al.,
2009). Although the mammalian Miro proteins interact with
Milton homologues (Fransson et al., 2006), the effect of loss of
Miro proteins on axonal mitochondrial transport in mammalian
Figure 4. Mfn2 and Mfn1 interact with Miro and Milton proteins, key components of microtubule-based mitochondrial trans-
port. HEK 293T cells were transiently transfectedwith the indicated epitope-tagged constructs, followed by immunoprecipitation
(IP) and immunoblotting. A, B, Both Mfn2 and Mfn1 were able to interact with Miro1 and Miro2 by coimmunoprecipitation. The
Mfn2:Miro2 interactionwas consistentlymore robust than theMfn2:Miro1 interaction, suggesting theremay be selectivity for the
formation of this complex. C–F, Mfn2 and Mfn1 interact with the Milton homologues OIP106 and GRIF1, proteins known to
function as linkers between mitochondria and kinesins motors. G, H, Neither Mfn2 nor Mfn1 coimmunoprecipitated with Kif5C,
indicating that they do not directly link mitochondria to kinesin. I, Additionally, Mfn2 was unable to interact with syntaphilin, an
outer mitochondrial membrane protein that anchors mitochondria to microtubules.
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cells has not been examined. We used lentivirally delivered siR-
NAs to knock downMiro1 orMiro2 (supplemental Fig. S1, avail-
able at www.jneurosci.org as supplemental material) (70%
transcript knockdown) in sensory neurons and analyzed the effect
on mitochondrial transport. Knockdown of Miro1 altered mito-
chondrial distribution in the soma but did not affect axonal
mitochondrial transport (supplemental Fig. S5, available at
www.jneurosci.org as supplemental material). In contrast,
knockdown of Miro2 markedly disrupted axonal mitochon-
drial motility (Fig. 5). The pattern of mitochondrial movements
on kymograph analysis was similar to that seen in Mfn2/ neu-
rons, with loss of fast, sustained movements (Fig. 5A,B). Unlike
loss of Mfn2, which produced concurrent mitochondrial fusion
and transport defects with smaller fragmented mitochondria,
loss ofMiro2 did not alter the length of axonalmitochondria (Fig.
5C). Mitochondria in Miro2-depleted neurons spent more time
paused between anterograde and retrograde movements, and
the velocity distributions were skewed toward slower velocities
(Fig. 5D,E). Of note, overexpression ofMiro2 inMfn2/ cultures
was not able to rescue transport deficits (data not shown). Together,
the fact thatMfn2 interacts directly with theMiro proteins, and that
loss of Mfn2 orMiro2 disrupts axonal mitochondrial transport in a
nearly identicalmanner, suggests thatbothMfn2andMiro2mustbe
present for proper axonal mitochondrial transport.
Disruption of mitochondrial fusion by knockdown of Opa1
does not affect the axonal transport of mitochondria
Some of the CMT2A disease mutant MFN2 alleles are unable to
mediate mitochondrial fusion (Detmer and Chan, 2007). Given
that loss of mitochondrial fusion leads to dissipation of  and
diminished oxidative phosphorylation
(Lodi et al., 2004; Chen et al., 2005), it is
possible that the observed alterations inmi-
tochondrial transport couldbe secondary to
loss of mitochondrial fusion. To investigate
whether diminishing mitochondrial fusion
directly or indirectly disrupts axonal mito-
chondrial transport, we used lentivirally
delivered siRNA to knockdownOpa1 (sup-
plemental Fig. S1, available at www.
jneurosci.org as supplemental material)
(90% transcript knockdown) in cultured
DRG neurons. Knockdown of Opa1 se-
verely disrupts mitochondrial fusion in
non-neuronal cells, leading to a decrease in
mitochondrial size similar to loss of Mfn1/
Mfn2 (Cipolat et al., 2004; Chen et al.,
2005). Measurement of mitochondrial
lengths confirmed that the mitochondria
were significantly shorter in Opa1 knock-
downDRG axons (Fig. 6C), consistent with
the expected decrease in mitochondrial fu-
sion (Cipolat et al., 2004; Chen et al., 2005).
However, time-lapse imaging and kymo-
graph analysis revealed that patterns
of mitochondrial movement in Opa1
knockdownneuronswere indistinguishable
from those of controls (Fig. 6A,B). Mito-
chondria inneuronsdepletedofOpa1 spent
equal amounts of time paused between
movements in anterograde and retrograde
directions and moved at similar velocities
compared with controls (Fig. 6D,E).
These data indicate that disrupting mitochondrial fusion
alone via Opa1 knockdown does not itself affect mitochon-
drial transport and further supports that Mfn2, via its interac-
tions with other proteins at the OMM, plays a direct role in
regulating mitochondrial transport.
CMT2A-associatedMFN2mutants cannot compensate for the
mitochondrial transport abnormality inMfn2/ neurons
As described above, studies in fibroblasts have shown that some
CMT2A-associated MFN2 mutants are unable to mediate mito-
chondrial fusion (R94Q), whereas others are fusion competent
(L76P, W740S) (Detmer and Chan, 2007). However, exogenous
expression of all of these mutants produced a mitochondrial
transport deficit in DRG neurons (Baloh et al., 2007), suggesting
that the ability of CMT2A mutants to mediate fusion and trans-
port may be separable. To determine whether the role of Mfn2 in
mitochondrial fusion could be dissociated from its role in trans-
port, we expressed the L76P andW740Smutants (fusion compe-
tent) and the R94Q mutant (fusion incompetent) in cultured
Mfn2/ neurons and assessed their ability to rescue the trans-
port defect. In contrast to wtMFN2, none of the CMT2A-
associated mutants were able to completely normalize the time
mitochondria spent paused between movements or to fully re-
store the faster movement segments seen on velocity distribu-
tions (Fig. 7A–C), with the fusion-incompetent R94Q allele being
least capable of rescuing the defect in transport inMfn2/ neu-
rons. Therefore, CMT2A MFN2 mutants were not able to nor-
malize axonal mitochondrial transport in DRG axons whether
they are fusion competent (L76P, W740S) or incompetent
(R94Q). This finding indicates that disruption of axonal mito-
Figure 5. Depletion ofMiro2 produces amitochondrial transport abnormality similar to that observedwith loss ofMfn2 in DRG
neurons. A, B, Kymograph analysis reveals that siRNA-mediated knockdown of Miro2 dramatically altered patterns of mitochon-
drial transport. C, Size–frequency histogram of axonal mitochondria demonstrated that depletion of Miro2 alteredmitochondrial
transportwithout changingmitochondrialmorphology.D, Similar toMfn2/ cultures,mitochondria spent agreater percentage
of time paused between anterogrademovements inMiro2 knockdown cultures (*p 0.001, t test; n is the number of axons from
which image stacks were created). Pauses between retrograde movements trended toward longer pause times but did not reach
statistical significance. E, Mitochondria velocity distributions were also skewed toward slower movements in Miro2 knockdown
cultures, similar to effects seen with loss of Mfn2.
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chondrial transport correlates better with
pathogenicity of CMT2A-associated
MFN2 mutants than with the loss of the
ability to mediate mitochondrial fusion.
Discussion
These experiments provide evidence for a
direct role for Mfn2 in mediating mito-
chondrial transport, distinct from its role in
mitochondrial fusion. Both loss of Mfn2
and expression of CMT2A-associated
MFN2 diseasemutants specifically altermi-
tochondrial movement patterns, causing
mitochondria (but not other organelles)
to move at slower velocities and pause for
greater lengths of time, consistent with
an inability to attach/move via the
microtubule-based kinesin and dynein
transport systems. Together with the find-
ing thatmitofusins interact withMiropro-
teins and OIP106/GRIF1, these data
indicate thatMfn2 is a key component of the
linker/adaptor complex between mitochon-
dria and kinesin/microtubules.
Mfn2 as a multifaceted regulator of
mitochondrial dynamics and function
Outer mitochondrial membrane proteins
are well positioned to play a key role in co-
ordinating and regulating diverse aspects of
mitochondrial function. Perhaps it should
not be a surprise then that mitofusins have
been reported to perform numerous func-
tions, including the regulation of mitochondrial fusion (Chan,
2006), endoplasmic reticulum (ER)–mitochondrial tethering (de
BritoandScorrano,2008), apoptotic cell deathandoutermembrane
permeability (Suen et al., 2008), oxidative phosphorylation and gra-
dient coupling (Pichet al., 2005), andmicrotubule-basedmitochon-
drial transport.
Our data indicate that regulation of mitochondrial transport
by Mfn2 is achieved by interacting with the Miro:
Milton complex. The increased pause time and slower movement
velocities in both anterograde and retrograde directions due to
loss of Mfn2 closely resemble the mitochondrial movement ab-
normalities seen in Miro2-depleted DRG neurons and in dMiro
knock-out flies (Russo et al., 2009). Other reports found that
overexpression of Miro proteins can either increase (Guo et al.,
2005) or decrease (Russo et al., 2009) axonal mitochondrial
transport. Importantly, we observed that overexpression of
Miro2 could not rescue the transport deficit in Mfn2/ neu-
rons, indicating that bothMfn2 andMiro2 are required to coop-
eratively mediate mitochondrial transport.
While Miro proteins have only been shown to interact with
anterogradely moving kinesin motors, loss of either Mfn2 or
Miro2 led to disruption of both anterograde and retrograde mi-
tochondrial transport, similar to loss of dMiro in flies (Russo et
al., 2009). The Mfn:Miro complex may also bind to dynein and
direct alternating engagements of either motor withmicrotubule
tracks. However, this does not have to be the case, as anterograde
and retrograde organellar transports are coordinately regulated,
and selective disruption of either kinesins or dynein/dynactin
typically diminishes bidirectional transport, though the exact
reason remains unclear (Brady et al., 1990; Waterman-Storer et
al., 1997; Martin et al., 1999; Deacon et al., 2003). The increased
time mitochondria spend paused in axons from neurons lacking
Mfn2 or Miro2 may also indicate a disruption of motor proces-
sivity. Together, this suggests that theMiro2:Mfn2 complex plays
a role in regulating the processivity of kinesin motors and in
orchestrating the switch between engaging anterogradelymoving
kinesins and retrogradely moving dyneins (Russo et al., 2009).
Given the interaction between Miro proteins and mitofusins,
it is perhaps not surprising that several studies have suggested
that Miro proteins may also influence mitochondrial morphol-
ogy and fusion. Examples include the expression of constitutively
active Miro1 producing long thread-like mitochondria in COS-7
cells, hippocampal neurons, andH9c2 cells (Fransson et al., 2006;
Saotome et al., 2008;MacAskill et al., 2009a), and the overexpres-
sion of dMiro inDrosophila increasing the mean length of axonal
mitochondria (Russo et al., 2009). These studies highlight the
notion that membrane transport and fusion are intimately re-
lated processes that must be coordinately regulated to achieve
proper organellar trafficking, and it is likely that molecular adap-
tor complexes at the outer mitochondrial membrane will serve
dual roles in transport and fusion.
Alterations in mitochondrial dynamics in human disease
Mitochondrial dysfunction is involved in numerous neurode-
generative and metabolic diseases; however, whether mitochon-
drial dysfunction plays a primary role in disease pathogenesis or
is simply a consequence of other aspects of cellular dysfunction
(disruption of protein homeostasis, environmental toxins, etc) is
unclear. In this context, studying the molecular mechanisms by
which mutations in mitochondrial proteins (such as MFN2 or
Figure 6. Disruption of mitochondrial fusion by knockdown of Opa1 does not alter mitochondrial axonal transport. To assess
whether disruptingmitochondrial fusion is itself sufficient to altermitochondrial transport, we used siRNA to knock down Opa1 in
DRG neurons. A, B, Embossed images of representative axons and the corresponding kymographs showing Opa1 knockdown
(90%) did not alter mitochondrial movement patterns. C, Mitochondrial size–frequency histogram showed that loss of Opa1
significantly decreased mitochondrial length similar to that seen in Mfn2/ cultures, reflective of decreased mitochondrial
fusion. D, E, Pause times between anterograde or retrograde movements (D) and velocity of movements (E) were not altered by
Opa1 knockdown (n is the number of axons from which kymographs were generated), unlike loss of Mfn2, indicating that loss of
mitochondrial fusion alone does not alter mitochondrial transport.
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OPA1) cause human disease is helpful, as altered mitochondrial
function likely plays a primary role in disease. One of the funda-
mental mysteries of inherited neurodegenerative diseases is the
selective vulnerability of particular populations of neurons to
mutations in universally expressed proteins. CMT2A and domi-
nant optic atrophy are associated with mutations in MFN2 and
OPA1, respectively; both are ubiquitously expressed proteins es-
sential for mitochondrial fusion (Alexander et al., 2000; Delettre
et al., 2000; Zuchner et al., 2004). However, instead of leading to
identical human diseases, mutations in MFN2 cause a severe pe-
ripheral neuropathy affecting the longest axons in the body,
whereas mutations in OPA1 (typically via haploinsufficiency)
predominantly lead to degeneration of optic nerve axons. Our
findings suggest that the fundamental difference in the pathogen-
esis of these diseases lies in the fact that loss of OPA1 disrupts
mitochondrial fusion without altering mitochondrial transport.
Interestingly, early changes in mitochondrial dynamics are seen
in neurons expressing mutant forms of neurofilament that cause
CMT2E, suggesting that alterations in mitochondrial transport
and distribution may be a final common pathway leading to ax-
onal degeneration in multiple types of CMT (Baloh, 2008;
Tradewell et al., 2009). A viable working hypothesis is that the
long peripheral nerves affected in CMT are more vulnerable to
disruption of mitochondrial transport and distribution than
other cell types. Defining evidence for or against this hypothesis
from patient samples or animal models remains to be demon-
strated and is a focus of ongoing research.
Although our studies indicate thatMfn2 is clearly required for
mitochondrial transport, the precise molecular mechanism by
which Mfn2 disease mutants disrupt this process remains un-
clear, as they maintain the ability to interact with Miro1/2 and
withOIP106/GRIF1. These data indicate theCMT2Adiseasemu-
tants do not simply disrupt formation of the molecular adaptor
complex linking mitochondria to kinesins, but instead disrupt
the proper function of this complex and, hence, further studies
will be needed to understand exactly how Mfn2 disease mutants
alter the properties of the adaptor complex on a molecular level.
The role of Mfn1 andMfn2 in controlling
mitochondrial dynamics
Alhough Mfn2 and Mfn1 are highly homologous proteins with
overlapping functions, several lines of evidence have shed light on
properties that are divergent between them. Mfn1 more effec-
tively tethersmitochondrial membranes and alone is sufficient to
mediate fusion with Opa1 (Cipolat et al., 2004; Ishihara et al.,
2004). Though both Mfn1- and Mfn2-null mice show early em-
bryonic lethality due to a placental defect (Chen et al., 2003), loss
ofMfn1 outside of the placenta (using a Cre-lox system) led to no
detectable abnormalities, whereas similar nonplacental loss of
Mfn2 caused severemultisystemdefects and early postnatal death
(Chen et al., 2007). Additionally, recent evidence suggested that
Mfn2 but not Mfn1 is involved in ER–mitochondrial tethering
(de Brito and Scorrano, 2008).
In our study, loss of Mfn2 alone is sufficient to produce a
severe mitochondrial transport deficit in DRG neurons that
could be restored by expression of either Mfn2 or Mfn1, consis-
tent with the fact that both can interact with the Miro:Milton
complex. Indeed, we found that exogenous expression of
Mfn1 was able to compensate for loss of Mfn2 in DRG neu-
rons, raising the possibility that identifying drugs that would
augment Mfn1 expression may represent a valid therapeutic
strategy for CMT2A.
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